I believe that COVID-19 has brought about a profound transformation in the healthcare landscape, and this transformation will persist. Even as we transition into an endemic phase of the virus, COVID-19 is not going to disappear; it will become a permanent presence, much like other viruses. Unfortunately, many patients are still not receiving the level of care they need, and the mortality rate remains unacceptably high.
This situation is far from what it should be. Our commitment to making a lasting impact in the field of COVID-19 treatment stems from a promise we made over a decade ago, recognizing the substantial unmet needs and understanding that we possess a unique advantage. With our three-plus decades of experience in developing antivirals, we are well-positioned to be part of the solution to this ongoing healthcare challenge.
Anu Osinusi is an infectious disease physician and Vice President of Clinical Research for Hepatitis, Respiratory, and Emerging Viruses at Gilead.
#COVIDTransformations #HealthcareEvolution #EndemicPhase #VirusImpact #PatientCare #MortalityRate #UnmetNeeds #AntiviralSolutions #HealthcareChallenge #COVIDTreatment
SUBSCRIBE TO THE PODCAST → https://www.kevinmd.com/podcast
RATE AND REVIEW → https://www.kevinmd.com/rate
FOLLOW ON INSTAGRAM → https://www.instagram.com/kevinphomd
FOLLOW ON TIKTOK → https://www.tiktok.com/@kevinphomd
